Prescription drug · ANDA
Gefitinib NDC 50742-366
Gefitinib 250 mg/1 · Tablet, Coated · Oral · Ingenus Pharmaceuticals, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50742-366-30 | 50742036630 | 30 TABLET, COATED in 1 BOTTLE (50742-366-30)Marketed from Apr 27, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Gefitinib
- Generic name (nonproprietary)
- gefitinib
- Active ingredients
- Gefitinib — 250 mg/1
- Dosage form
- Tablet, Coated
- Route
- Oral
- Labeler
- Ingenus Pharmaceuticals, LLCNDC labeler code 50742
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 211591
- Marketing start
- Listing expires
- Other FDA classes
- Protein Kinase Inhibitors (Mechanism)
- Identifiers
- Product ID 50742-366_932e3701-75ae-438f-bb6a-2c2662c73ee5SPL ID 932e3701-75ae-438f-bb6a-2c2662c73ee5SPL set ID 6402435f-9f6a-4f02-91a2-6267d783fa78RxCUI 349472UNII S65743JHBS
- Pharmacologic class
- Kinase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N450742036630followed by a unit qualifier and the quantityPackage 50742-0366-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Gefitinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [ see Clinical Studies (14) ]. Limitation of Use: Safety and efficacy of gefitinib tablets have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations [ see Clinical Studies (14) ]. Gefitinib tablets are a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung…
Excerpt only. Read the full label for complete information.
About NDC 50742-366
- What is NDC 50742-366?
- 50742-366 is the product NDC for Gefitinib, Gefitinib 250 mg/1 tablet, coated, listed with the FDA by Ingenus Pharmaceuticals, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Gefitinib.
- What is the active ingredient?
- Gefitinib.
- Who is the labeler?
- Ingenus Pharmaceuticals, LLC, NDC labeler code 50742. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Gefitinib?
- 3 other product NDCs are listed under this name. See all Gefitinib NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Gefitinib products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Gefitinib | Gefitinib 250 mg/1 | Tablet, Film coatedOral | Teva Pharmaceuticals, Inc. | 0480-4053 | 00480-4053-56 |
| Gefitinib | Gefitinib 250 mg/1 | Tablet, Film coatedOral | Natco Pharma USA LLC | 69339-168 | 69339-0168-03 |
| Gefitinib | Gefitinib 250 mg/1 | Tablet, CoatedOral | Qilu Pharmaceutical Co., Ltd. | 67184-0531 | 67184-0531-0167184-0531-0267184-0531-03 |
Other NDCs under ANDA 211591
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Gefitinib | Gefitinib 250 mg/1 | Tablet, CoatedOral | Qilu Pharmaceutical Co., Ltd. | 67184-0531 |